替雷利珠单抗联合紫杉醇+卡铂治疗Ⅳ期肺鳞状细胞癌的疗效及对患者T淋巴细胞亚群的影响  

Efficacy of tislelizumab combined with paclitaxel and carboplatin in the treatment of stage IV lung squamous cell carcinoma and its influence on T lymphocyte subsets

作　　者：段冬冬 赵景景 李冯洋 DUAN Dongdong;ZHAO Jingjing;LI Fengyang(Ward I,Department of Respiratory and Critical Care Medicine,Zhumadian Central Hospital,Zhumadian 463000,He’nan,China)

机构地区：[1]驻马店市中心医院呼吸与危重症医学科一病区,河南驻马店4630000

出　　处：《癌症进展》2025年第3期294-296,320,共4页Oncology Progress

摘　　要：目的 探讨替雷利珠单抗联合紫杉醇^(+)卡铂治疗Ⅳ期肺鳞状细胞癌的疗效及对患者T淋巴细胞亚群的影响。方法 根据治疗方法的不同将98例肺鳞状细胞癌患者分为联合组(n=50)和对照组(n=48),对照组患者接受紫杉醇^(+)卡铂治疗,联合组患者接受替雷利珠单抗联合紫杉醇^(+)卡铂治疗。比较两组患者的临床疗效、T淋巴细胞亚群(CD3^(+)、CD4^(+)、CD8^(+),计算CD4^(+)/CD8^(+))、不良反应发生情况和预后情况。结果 治疗后,联合组患者CD3^(+)、CD4^(+)水平及CD4^(+)/CD8^(+)均高于对照组,CD8^(+)水平低于对照组,差异均有统计学意义(P﹤0.05)。联合组患者的疾病控制率为68.00%,高于对照组患者的47.92%,差异有统计学意义(P﹤0.05)。治疗后,两组患者肝功能异常、食欲减退、全血细胞减少发生率比较,差异均无统计学意义(P﹥0.05)。随访1年,联合组患者生存率为68.00%,高于对照组患者的47.92%,差异有统计学意义(P﹤0.05)。结论 替雷利珠单抗联合紫杉醇^(+)卡铂治疗Ⅳ期肺鳞状细胞癌患者,可改善患者的T淋巴细胞亚群水平,提高临床疗效,从而改善患者的预后。Objective To investigate efficacy of tislelizumab combined with paclitaxel and carboplatin in the treatment of stage IV lung squamous cell carcinoma and its influence on T lymphocyte subsets.Method According to different treatment methods,98 patients with lung squamous cell carcinoma were divided into combination group(n=50)and control group(n=48).Patients in the control group received paclitaxel^(+)carboplatin treatment,while patients in the combination group received tislelizumab combined with paclitaxel^(+)carboplatin treatment.The clinical efficacy,T lymphocyte subsets(CD3^(+),CD4^(+),CD8^(+),CD4^(+)/CD8^(+)),incidence of adverse reactions,and prognosis were compared between the two groups.Result After treatment,the levels of CD3^(+),CD4^(+)and CD4^(+)/CD8^(+)in combination group were higher than those in control group,the level of CD8^(+)was higher than that in control group,and the differences were statistically significant(P<0.05).The disease control rate in combination group was 68.00%,which was higher than the 47.92%of the control group,and the difference was statistically significant(P<0.05).After treatment,there were no statistically significant differences in the incidences of abnormal liver function,decreased appetite,and decreased whole blood cells between the two groups(P>0.05).After one-year follow-up,the survival rate in combination group was 68.00%,which was higher than 47.92%in the control group,and the difference was statistically significant(P<0.05).Conclusion Tislelizumab combined with paclitaxel^(+)carboplatin in the treatment of stage IV lung squamous cell carcinoma patients,can improve the levels of T lymphocyte subsets,enhance clinical efficacy,and thus improve the prognosis.

关 键 词：替雷利珠单抗 紫杉醇 卡铂 肺鳞状细胞癌 T淋巴细胞亚群 预后 

分 类 号：R734.2[医药卫生—肿瘤]